762 / 1195
RECOMMENDATION:
Reviewer #
Do you recommend that the ERP adopt this method as an AOAC
Official Methods of Analysis (First
Action status)
1
Yes
2
Yes
3
4
Yes, with the minor changes as recommended.
5
Yes
6
Recommended.
7
If above concerns are satisfactorily addressed to the satisfaction of those present for the discussion, I
would support recommending the adoption of this method for first action status.
AFTER FIRST ACTION STATUS:
Reviewer #
Is there any additional information that the ERP should consider in order to recommend the
method for Final Action status?
1
No
2
Single laboratory study with L. marthii, L. rocourtiae, L. fleischmanii, and L. weihenstephanensis to
confirm expected exclusivity.
3
4
Not that I am aware.
5
6
7
Consider additional data be generated for both broths (LPT and LMX) for matrices not covered in the
studies for the specific broth.
Reviewer #
Comments:
1
2
No further comments.
3
4
No additional comments.
5
no
6
7
SAFETY
The additional risks identified require clarification(s) so as to ensure that the manuscript corresponds
to the approved study protocol and safety guidance
(See comment):
Comment:
A safety caution is included in the VIDAS LMX package insert and the CDC website is cited in the
references, while in the comparative evaluation study of the VIDAS
Listeria monocytogenes
Express
(LMX) a safety caution is included in the text. It may be helpful that users have a safety caution in the
method where they are directed to the CDC website for biosafety information dealing with
pathogens http:/www.cdc.gov/biosafety/publications/bmb15/index.htm/
8
21 June 2013